Syngene International, a contract research, development and manufacturing organisation (CRDMO) has announced that its newly upgraded biologics facility ‘Unit 3’ would be operational for clinical and commercial supply in the second half of 2024. The facility will be available for
Syngene International Contract Manufacturing & Development (CDMO) Profile Syngene is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies. Syngene’s clients are world
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
